title: The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men.
abstract: BACKGROUND
  Whether men with lifelong premature ejaculation (PE) prefer on-demand drug treatment to delay ejaculation time to daily drug treatment, has never been studied as a separate study question.
  
  
  OBJECTIVE
  To study how men with lifelong PE feel about the use of serotonergic antidepressants, and which option they would prefer for themselves: either a daily drug, a drug to be used on demand, or a topical anesthetic cream to be applied on demand.
  
  
  METHODS
  Treatment preference was determined by questionnaire.
  
  
  METHODS
  An observational questionnaire survey in a clinical sample. Preferences of different treatment strategies were queried before and after standard efficacy and safety information.
  
  
  RESULTS
  A consecutive group of 88 men with lifelong PE who decided for themselves to be seen for rapid ejaculation was studied. The age was 37 +/- 11 years (mean +/- SD), range 18-64 years. None of these men was ever treated for PE and 21% used medication that did not affect sexual performance. Of them, 71 (81%) preferred a drug for daily use, 14 (16%) a drug on demand, while three men preferred topical anesthetic cream. Those men who initially preferred daily treatment did not change their view after standard information about efficacy and side effects, while 9 of 17 men who initially preferred on-demand drug treatment had switched their preferences to daily oral drug usage. Around 60% of men did not care about the nature of the drug, i.e., an antidepressant. The most frequently reported argument to prefer daily drug treatment was that this strategy would have the least effects toward the spontaneity of having sex.
  
  
  CONCLUSIONS
  As opposed to agents that must be taken 4-6 hours prior to coitus and with the methods used here, this group of Dutch men with lifelong PE favor uninterrupted daily drug treatment to delay ejaculation mainly because daily treatment guarantees no interference with the spontaneity of having sex.
authors.affiliation: Department of Psychiatry and Neurosexology, HagaHospital Leyenburg, Leyweg 275, 2545 CH The Hague, The Netherlands. md@waldinger.demon.nl
authors.forename: Marcel D
authors.initials: MD
authors.lastname: Waldinger
authors.forename: Aeilko H
authors.initials: AH
authors.lastname: Zwinderman
authors.forename: Berend
authors.initials: B
authors.lastname: Olivier
authors.forename: Dave H
authors.initials: DH
authors.lastname: Schweitzer
mesh_terms: D000328:Adult; D001596:Benzylamines / Q000008:administration & dosage; D002997:Clomipramine / Q000008:administration & dosage; D015331:Cohort Studies; D003075:Coitus; D004305:Dose-Response Relationship, Drug; D004542:Ejaculation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage; D009426:Netherlands; D017374:Paroxetine / Q000008:administration & dosage; D017060:Patient Satisfaction; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy*; D014147:Tramadol / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001596:Benzylamines; D002997:Clomipramine; D009281:Naphthalenes; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D014147:Tramadol; C080598:dapoxetine